Zobrazeno 1 - 10
of 39
pro vyhledávání: '"Stephen Falk"'
Autor:
Janet Graham, Mahesh K. B. Parmar, Emma Yates, Tim Maughan, Jenny F. Seligmann, Louise Brown, David Fisher, Kai-Keen Shiu, Fiona Collinson, Ewan Brown, Philip Quirke, Stephen Falk, Richard H. Wilson, Susan D. Richman, Gary Middleton, Harpreet Wasan, Richard Kaplan, Richard Adams, Rachel Butler, Matthew T. Seymour, Leslie Samuel
Publikováno v:
Journal of Clinical Oncology. 39:3693-3704
PURPOSE Despite extensive randomized evidence supporting the use of treatment breaks in metastatic colorectal cancer (mCRC), they are not universally offered to patients despite improvements in quality of life without detriment to overall survival (O
Autor:
John V. Reynolds, Shaun R. Preston, Brian O'Neill, Maeve Aine Lowery, Lene Baeksgaard, Thomas Crosby, Moya Cunningham, Sinead Cuffe, Gareth Owen Griffiths, Rajarshi Roy, Stephen Falk, George Hanna, Frederick R. Bartlett, Imelda Parker, Alberto Alvarez-Iglesias, Magnus Nilsson, Guillaume Piessen, Signe Risum, Narayanasamy Ravi, Raymond S. McDermott
Publikováno v:
Journal of Clinical Oncology. 41:295-295
295 Background: The optimum combination curative approach to locally advanced adenocarcinoma of the esophagus and esophago-gastric junction (AEG) remains controversial, specifically whether multimodal therapy or perioperative chemotherapy is superior
Autor:
Susan D. Richman, Jenny F. Seligmann, Philip Quirke, Tim Maughan, Focus Investigators, Emma Yates, Richard Kaplan, Rachel Butler, Ewan Brown, Matthew T. Seymour, Richard H. Wilson, Louise Brown, Richard Adams, David Fisher, Stephen Falk, Janet Graham, Fiona Collinson
Publikováno v:
Journal of Clinical Oncology. 39:3504-3504
3504 Background: There is extensive randomised evidence supporting the use of treatment breaks in mCRC, but breaks from treatment are not universally offered to patients despite reductions in toxicity, without detriment to OS. Prior trials have shown
Autor:
Stephen Falk, Susan J Dutton, Wasat Mansoor, David A J Stevenson, Caroline Clark, Russell D. Petty, Aileen Osborne, Asa Dahle-Smith, Angel Garcia-Alonso, Mark Harrison, Joyce Thompson, Graeme I. Murray, Ian Chau, Irene Chong, Jonathan Wadsley, Corran Roberts, Doreen Massie, Zosia Miedzybrodzka, Anirban Chatterjee, Sean Elyan, David Walter Fyfe, David Ferry
Publikováno v:
Journal of Clinical Oncology. 35:2279-2287
Purpose The Cancer Esophagus Gefitinib trial demonstrated improved progression-free survival with the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib relative to placebo in patients with advanced esophageal cancer who had
Autor:
Tanios Bekaii-Saab, Frank Beier, Svenja Adrian, Josep Tabernero, Elena Elez, Jana Prausová, Cindy Neuzillet, Zev A. Wainberg, Eva Liu, Kanwal Pratap Singh Raghav, Filippo Pietrantonio, Stephen Falk, Shaista Salim, Nicole Campbell, Salvatore Siena, Eric Van Cutsem, Nicolas Isambert, Regina Esser
Publikováno v:
Journal of Clinical Oncology. 39:TPS149-TPS149
TPS149 Background: METamp is a secondary, or co-driving, genetic change in pts with mCRC and acquired resistance to anti-EGFR therapy, which can contribute to disease progression. In EGFR-resistant pts with mCRC and METamp, MET inhibition + an anti-E
Publikováno v:
Journal of Clinical Oncology. 39:198-198
198 Background: Optimal neoadjuvant (NA) treatment for adenocarcinoma of the esophagus and esophagogastric junction is unknown. This study aims to evaluate an approach of offering NA chemoradiotherapy (CRT) to T3/T4 tumours with a threatened circumfe
Autor:
Juan W. Valle, Eftychia E. Psarelli, John P. Neoptolemos, Paula Ghaneh, Jakob R. Izbicki, Daniel H. Palmer, David Cunningham, Thomas Crosby, Stephen Falk, Ralf Segersvärd, Harpreet Wasan, Pascal Hammel, Tim Meyer, Alan Anthoney, Markus W. Büchler, Gary Middleton, Jonathan Wadsley, Paul Ross, A. C. McDonald, Bengt Glimelius
Publikováno v:
Journal of Clinical Oncology. 38:4516-4516
LBA4006 Background: The ESPAC-3 trial compared adjuvant GEM with 5-fluorouracil/folinic acid for resected pancreatic cancer. GEM is the standard of care based on similar survival and less toxicity. ESPAC-4 aimed to determine whether combination chemo
Autor:
Stephen Falk, A.S. Dhadda, Robert J Harte, Rob Glynne-Jones, Andre Lopes, Vivek Misra, Mark Harrison, Richard Adams, Leslie Samuel, Marian Duggan, Arthur Sun Myint, Nicholas P. West, Nicholas R Brown, Simon P. Bach, Gina Brown, Philip Quirke, David Sebag-Montefiore, Simon Gollins, Philip Parsons, Laura White
Publikováno v:
Journal of Clinical Oncology. 38:4101-4101
4101 Background: Phase II studies reported high pathological complete response (pCR) rates and acceptable toxicity using irinotecan and fluoropyrimidine chemoradiation in LARC (ISRCTN:09351447). Methods: This phase III, multicentre, open-label trial
Autor:
Tim Maughan, Wendy Wade, Catrin Cox, David Sebag-Montefiore, Somnath Mukherjee, Maria A. Hawkins, Gareth Griffiths, R. Maggs, Ganesh Radhakrishna, Ruby Ray, Ricky A. Sharma, Tom Crosby, Heike I. Grabsch, Jo Canham, Simon Gollins, Andrew Bateman, Sarah Gwynne, Chris Nicholas Hurt, Stephen Falk, Rajarshi Roy
Publikováno v:
Journal of Clinical Oncology. 38:373-373
373 Background: Initial results of the NEOSCOPE trial comparing pre-operative CarPac vs OxCap based chemoradiotherapy (CRT) in patients with adenocarcinoma of the oesophagus or oesophagogastric junction showed comparable toxicity and improvement in p
Autor:
Rajarshi Roy, Tania Tillett, Galina Velikova, Matthew T. Seymour, Simon Aird Grumett, Peter Hall, Helen Marshall, Angel Garcia, Jonathan Nicoll, Jonathan Wadsley, Sharon Ruddock, Christine Allmark, Daniel Swinson, Stephen Falk, Justin S. Waters, Russell D. Petty, Heike I. Grabsch, Eszter Katona, Sebastian Cummings, Konstantinos Kamposioras
Publikováno v:
Journal of Clinical Oncology. 37:4006-4006
4006 Background: Many pts with aGOAC are elderly and/or frail. We previously compared epirubin/ oxaliplatin/ capecitabine (EOCap) vs OCap vs Cap in a pick-the-winner study and found OCap best. GO2 was designed to find the optimum dose of OCap and to